Deprenyl suppresses the oxidant stress associated with increased dopamine turnover

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Annals of Neurology

• Publication date

  1989-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/ana.410260518PMID 2510589
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil

  2005cited by this paper
• Clinical Actions of l-Deprenyl in Parkinson’s Disease

  1989cited by this paper
• Dopamine turnover and glutathione oxidation: implications for Parkinson disease.

  1989cited by this paper
• Alz-50, Ubiquitin and Tau Immunoreactivity of Neurofibrillary Tangles, Pick Bodies and Lewy Bodies

  1988cited by this paper
• Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.

  1988cited by this paper
• Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP.

  1988cited by this paper
• The Biochemical Basis of Neuropharmacology, 5th ed

  1987cited by this paper
• Reduced and oxidized glutathione in human and monkey brain.

  1987cited by this paper
• Monoamine oxidase, hydrogen peroxide, and Parkinson's disease.

  1987cited by this paper
• Biochemical pathophysiology of Parkinson's disease.

  1987cited by this paper
• Drug trial for Parkinson's.

  1987cited by this paper
• Glutathione and Ascorbate During Ischemia and Postischemic Reperfusion in Rat Brain

  1980cited by this paper
• Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.

  1980cited by this paper
• FREE AMINO ACIDS AND RELATED COMPOUNDS IN BIOPSIES OF HUMAN BRAIN

  1971cited by this paper

• Effects of electroconvulsive shock on astroglial reactivity in a rat model of antipsychotic-induced neurotoxicity

  2025cites this paper
• Oxidation of dopamine and related catechols in dopaminergic brain regions in Parkinson’s disease and during ageing in non-Parkinsonian subjects

  2024cites this paper
• Haloperidol and Other Antipsychotics Exposure before Endometrial Cancer Diagnosis: A Population-based Case-control Study

  2022cites this paper
• Synthesis and evaluation of chromone derivatives as inhibitors of monoamine oxidase

  2019cites this paper
• Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease

  2018cites this paper
• Antioxidant and antiapoptotic actions of selegiline protect against 3-NP-induced neurotoxicity in rats

  2017cites this paper
• Synthesis, Docking and Evaluation of Novel Pyrazole Carboxamide Derivatives as Multifunctional Anti-Alzheimer's Agents

  2017cites this paper
• Genetic elimination of dopamine vesicular stocks in the nigrostriatal pathway replicates Parkinson’s disease motor symptoms without neuronal degeneration in adult mice

  2017cites this paper
• Monoamine Oxidase B Inhibitors in Parkinson's Disease.

  2017cites this paper
• Discovery of catechol-O-methyltransferase inhibitors through virtual screening

  2016cites this paper
• Therapeutic Perspective on Tardive Syndrome with Special Reference to Deep Brain Stimulation

  2016cites this paper
• Physical exercise prevents short and long-term deficits on aversive and recognition memory and attenuates brain oxidative damage induced by maternal deprivation.

  2015cites this paper
• 348-352-Mohammed Reza-Gold nanoparticles-Feb 11 2015

  2015cites this paper
• The Effect of Gold Nanoparticle on Luteinizing Hormone, Follicle StimulatingHormone, Testosterone and Testis In Male Rat.

  2015cites this paper
• Toxic effects of Mn2O3 nanoparticles on rat testis and sex hormone

  2015cites this paper
• Syntheses of 8–(phenoxymethyl)caffeine analogues and their evaluation as inhibitors of monoamine oxidase and as antagonists of the adenosine A2A receptor

  2013cites this paper
• Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

  2013cites this paper
• Evidence of oxidative stress in young and aged DJ‐1‐deficient mice

  2013cites this paper
• Emerging Therapies in the Pharmacological Treatment of Parkinson’s Disease

  2012cites this paper
• Design, synthesis and inhibitory activities of 8-(substituted styrol-formamido)phenyl-xanthine derivatives on monoamine oxidase B.

  2012cites this paper
• Morin Attenuates Haloperidol Induced Tardive Dyskinesia and Oxidative Stress in Mice

  2012cites this paper
• Mitochondria, monoamine oxidase B and Parkinson’s disease

  2012cites this paper
• R-Deprenyl: Pharmacological Spectrum of its Activity

  2010cites this paper
• Transport and biological impact of manganese

  2010cites this paper
• Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes.

  2010cites this paper
• Design and synthesis of heterocyclic compounds for neuroprotective enzyme interactions

  2010cites this paper
• Half a century of L-DOPA.

  2009cites this paper
• Effect of alpha lipoic acid on the tardive dyskinesia and oxidative stress induced by haloperidol in rats

  2009cites this paper
• The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na+, K+)-, Mg2+-ATPase activities, antioxidant status, and learning performance of aged rats

  2008cites this paper
• Configuration of crosslinked multi-polymeric multi-units for site-specific delivery of nicotine

  2008cites this paper
• Increase of monoamine oxidase-B activity in the brain of scrapie-infected hamsters.

  2008cites this paper
• Gene Association Studies of Schizophrenia and Tardive Dyskinesia

  2008cites this paper
• Effect of MAO-B Inhibition against Ischemia-induced Oxidative Stress in the Rat Brain

  2008cites this paper
• Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease

  2007cites this paper
• Balancing Short-Term Symptom Control and Long-Term Functional Outcomes in Patients with Parkinson's Disease

  2007cites this paper
• A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.

  2007cites this paper
• Oxidative stress and Parkinson's disease.

  2007cites this paper
• The neuroprotective effects of (-)deprenyl in an in vivo stroke model and in an in vitro hypoxia model

  2007cites this paper
• Neuroprotection in Parkinson's disease: clinical trials.

  2007cites this paper
• Advances in the treatment of Parkinson's disease.

  2007cites this paper
• Amine oxidases in apoptosis and cancer.

  2006cites this paper
• L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.

  2006cites this paper
• Neuroprotective and Neurotoxic Effects of L-DOPA in Rat Midbrain Dopaminergic Neurons in Culture

  2005cites this paper
• MPTP-induced deficits in motor activity: Neuroprotective effects of the spintrapping agent, α-phenyl-tert-butyl-nitrone (PBN)

  2005cites this paper
• Pergolide can induce soluble Superoxide dismutase in rat striata

  2005cites this paper
• The effect of long-term treatment with deprenyl on basal and L-DOPA evoked dopamine release in vitro from the corpus striatum of aged rats

  2005cites this paper
• Effect of pergolide on endogenous and exogenous L-DOPA metabolism in the rat striatum: a microdialysis study

  2005cites this paper
• Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity

  2005cites this paper
• Trial of subtherapeutic pergolide in de novo Parkinson's disease

  2005cites this paper
• Effect of L-dopa, oxyferriscorbone and ferrous iron on in vivo lipid peroxidation

  2005cites this paper
• Memantine, amantadine, and L-deprenyl potentiate the action of L-DOPA in monoamine-depleted rats

  2005cites this paper
• Age-dependent effects of maternal deprivation on oxidative stress in infant rat brain.

  2005cites this paper
• Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rat brain

  2005cites this paper
• Monoamine oxidase inhibitors in Parkinson’s disease

  2005cites this paper
• Effects of maternal deprivation on melatonin production and cognition in adolescent male and female rats.

  2005cites this paper
• Drug treatment of Parkinson's disease

  2004cites this paper
• Manganese exposure and induced oxidative stress in the rat brain.

  2004cites this paper
• Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinson's disease.

  2004cites this paper
• Parkinson's disease.

  2004cites this paper
• Monoamine oxidase-B inhibition in Alzheimer's disease.

  2004cites this paper
• Pharmacological aspects of (-)-deprenyl.

  2004cites this paper
• Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline.

  2004cites this paper
• D‐deprenyl protects nigrostriatal neurons against 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurotoxicity

  2003cites this paper
• The dose determination of deprenyl on the spinal cords motoneurons after sciatic nerve transection

  2003cites this paper
• Neuroprotection in Parkinson's disease: Clinical trials

  2003cites this paper
• Lack of Influence of the Apolipoprotein E Genotype on the Outcome of Selegiline Treatment in Alzheimer’s Disease

  2003cites this paper
• Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B

  2003cites this paper
• Selegiline long-term effects on brain acetylcholinesterase, (Na+,K+)-ATPase activities, antioxidant status and learning performance of aged rats.

  2003cites this paper
• Protective effect of N‐(2‐propynyl)‐2‐(5‐benzyloxy‐indolyl) methylamine (PF 9601N), a novel MAO‐B inhibitor, on dopamine‐lesioned PC12 cultured cells

  2003cites this paper
• Oxidative Mechanisms and Tardive Dyskinesia

  2003cites this paper
• Preclinical versus clinical neuroprotection.

  2003cites this paper
• Neuroprotective Strategies in Parkinson’s Disease

  2003cites this paper
• Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.

  2002cites this paper
• The effect of deprenyl washout in patients with long-standing Parkinson's disease

  2002cites this paper
• The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

  2002cites this paper
• Relationship between adverse effects of antipsychotic treatment and dopamine D2 receptor polymorphisms in patients with schizophrenia

  2002cites this paper
• Pharmacological approaches to disease-modifying therapies in Parkinson’s disease

  2002cites this paper
• Role of Oxidative Stress and Antioxidants in Neurodegenerative Diseases

  2002cites this paper
• Caloric restriction mimetics

  2002cites this paper
• Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-)-deprenyl in vivo.

  2001cites this paper
• (-)-D-Deprenyl attenuates apoptosis in experimental brain ischaemia.

  2001cites this paper
• Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain.

  2001cites this paper
• Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics.

  2001cites this paper
• Diet-related prevention of Alzheimer's disease: different hypotheses.

  2001cites this paper
• Glutamate induces oxidative stress not mediated by glutamate receptors or cystine transporters: protective effect of melatonin and other antioxidants

  2001cites this paper
• Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.

  2001cites this paper
• Role of Free Radicals in the Neurodegenerative Diseases

  2001cites this paper
• Effects of footshock stress on superoxide dismutase and glutathione peroxidase enzyme activities and thiobarbituric acid reactive substances levels in the rat prefrontal cortex and striatum.

  2000cites this paper
• Changes in spinal serotonin turnover mediate age-related differences in the behavioral manifestations of peripheral nerve injury.

  2000cites this paper
• Advances in Research on Neurodegeneration

  2000cites this paper
• Neuronal cell death in Huntington's disease: a potential role for dopamine.

  2000cites this paper
• MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders?

  2000cites this paper
• Assessment and Treatment of Dementia in Medical Patients

  2000cites this paper
• Alzheimer's Disease: Pharmacological Treatment and Management

  2000cites this paper
• Calpain Upregulation in Spinal Cords of Mice with 1‐Methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐induced Parkinson's Disease

  2000cites this paper
• Effect of MAO‐B Inhibitors on MPP+ Toxicity in Vivo

  2000cites this paper
• Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl.

  2000cites this paper
• Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling.

  2000cites this paper
• Early Parkinson’s Disease

  2000cites this paper
• Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease

  2000cites this paper